## MRK: Merck & Co., Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%); PEG 1.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($102.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Banque Pictet & Cie SA Sells 246,821 Shares of Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20260102T083921 | Neutral | Relevance: 100%
- Banque Pictet & Cie SA has significantly reduced its stake in Merck & Co., Inc. by selling 246,821 shares, representing a 23.8% cut. This leaves the firm with 788,353 shares valued at approximately $66.17 million. Simultaneously, Merck's EVP David Michael Williams also sold a portion of his holdings, further indicating insider activity.

**2. Merck stock dips after hours as 2025 ends; MRK investors shift focus to Feb. 3 earnings**
- Source: ts2.tech | 20260101T010711 | Somewhat-Bearish | Relevance: 100%
- Merck (MRK) shares slipped about 0.7% in after-hours trading as 2025 ended, with investors now looking forward to its fourth-quarter 2025 earnings call on February 3rd. Concerns include the sustainability of growth beyond its blockbuster cancer drug, Keytruda, which faces patent expiry in 2028. Analysts will be keen to see any changes to 2026 guidance, updates on pipeline programs, and capital allocation strategies.

**3. Where is Merck & Co. (MRK) Headed?**
- Source: Finviz | 20251231T170754 | Bullish | Relevance: 100%
- Merck & Co. (MRK) has made significant moves, including a historic agreement with the Trump administration to ensure medicine accessibility and affordability, and positive Phase 3 clinical trial results for KEYTRUDA plus Padcev in bladder cancer. The company is poised for growth in both its pharmaceutical and animal health segments, making it an affordable stock with good earnings growth potential. However, the author alludes that some AI stocks may offer better upsides.

**4. Merck & Co., Inc. (NYSE:MRK) Trading 1.2% Higher - Time to Buy?**
- Source: MarketBeat | 20260102T225709 | Somewhat-Bullish | Relevance: 100%
- Merck & Co., Inc. (NYSE:MRK) shares rose 1.2% to $106.48 on Friday with lower-than-average trading volume. Analyst sentiment is mixed, holding a consensus "Hold" rating with an average target of $110.13, though some firms have recently increased their price targets and ratings. The company recently raised its quarterly dividend to $0.85, offering a 3.2% yield, and reported Q1 EPS of $1.94.

**5. PICTET BANK & TRUST Ltd Decreases Stock Position in Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20260102T125508 | Neutral | Relevance: 100%
- PICTET BANK & TRUST Ltd significantly reduced its stake in Merck & Co., Inc. by 78.3% in Q3, selling 10,973 shares and retaining 3,040 shares valued at approximately $255,000. Despite this, other institutional investors have recently increased their holdings in Merck. The company has a current market capitalization of $261.11 billion and recently increased its quarterly dividend to $0.85 per share, representing a 3.2% yield.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | BMO Capital | $130 | $82 | +59% |
| 2025-12-15 | B of A Securiti | $120 | $105 | +14% |
| 2025-12-12 | Morgan Stanley | $102 | $100 | +2% |
| 2025-12-04 | Scotiabank | $120 | $105 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | BMO Capital | up | Outperform |
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-04 | Scotiabank | main | Sector Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($1.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.2% (-0.3%)
- Blackrock Inc.: 8.7% (-1.6%)
- State Street Corpora: 4.8% (-0.3%)
- Wellington Managemen: 3.0% (-2.0%)
- JPMORGAN CHASE & CO: 2.8% (+121.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 4 raises (avg +22%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Quality metrics strong (ROE 40%, ROA 14%, margin 30%). Balance sheet: $6.8B free cash flow. Analyst sentiment positive (4 raises, avg +22%). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $265.9B |
| Beta | 0.30 |
| 52W Range | $73.31 - $107.59 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 12.9 |
| Current P/E | 11.9 |
| YoY Growth | -7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.9% over 5 days). Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.13% (CS: 77) | Neutral |
| RSI_14 | 67.0 | Neutral |
| MACD Histogram | 0.13 | Bullish |
| vs SMA20 | 1.044x | Above |
| vs SMA50 | 1.106x | Above |
| vs SMA200 | 1.243x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $106.45
- **Stop Loss:** $102.07 (4.1% risk)
- **Target:** $110.83 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 328
- **Position Value:** $34,915.60
- **Portfolio %:** 34.92%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-03 (Est: $2.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.58 | +9.9% |
| 2025Q2 | $2.03 | $2.13 | +5.0% |
| 2025Q1 | $2.14 | $2.22 | +4.0% |
| 2024Q4 | $1.67 | $1.72 | +3.3% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*